Stock Financial Ratios, Dividends, Split History

XL / XL Group Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price55.74
Volume3,973,400.00
Market Cap ($M)14,320.44
Enterprise Value ($M)15,718.26
Book Value / Share38.33
Price / Book1.45
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 259,894,000
Common Stock Shares Outstanding 256,034,000
Weighted Average Number Of Diluted Shares Outstanding 259,894,000
Common Shares Outstanding 256,915,044
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.04
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.04
Balance Sheet (mrq) ($M)
Assets63,436.24
Liabilities51,974.92
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues11,328,157,000.00
Net Income-490.14
Earnings Per Share Basic-2.16
Earnings Per Share Diluted-2.16
Cash Flow Statement (mra) ($M)
Cash From Operations33.32
Cash from Investing662.73
Cash from Financing33.32
Identifiers and Descriptors
CUSIPG98290102
Central Index Key (CIK)875159
Related CUSIPS
G98290952 B5LRLL200 SB5LRLL23 G98290OLD G98294954 0G9829010 G98294104 G98290902 G98294904

Split History

Stock splits are used by XL Group Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Markel or XL Group: Which Insurer to Bet on Post Q1 Results?

2018-05-23 zacks
The insurance industry witnessed a change of fortunes in the first quarter of 2018 driven by better-than-expected performance mainly fueled by improving interest rates and economy, significantly lower catastrophe loss along with noteworthy tax reform effective Jan 1, 2018. Consequently, the industry is anticipated to deliver better-than-expected results and continue the momentum in the near term as well. (4-0)

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (1229-5)

Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219. (1403-8)

French insurer Axa finds tepid appetite for US business as IPO comes up $1 billion short

2018-05-10 cnbc
Axa SA's $15.3 billion takeover of global property casualty firm XL Group was a monster deal in the insurance world, but Paris-based Axa's plan to pay for the acquisition has come up short. (7-0)

UPDATE 1-AXA's U.S. arm raises $2.75 bln in IPO, misses target -source

2018-05-09 reuters
(Reuters) - French insurer AXA SA’s (AXAF.PA) initial public offering (IPO) of its U.S. division raised $2.75 billion by pricing at $20 per share on Wednesday, below its targeted range of $24-27 per share, a person familiar with the matter said. (14-0)

CUSIP: G98290102